T0	FollowUp 15987 16073	did not call patients back for study visits for detailed assessment of quality of life
T1	OTHER 16611 16679	do not have complete information about adherence to study medication
T2	OutcomeAssessor 16849 16875	unmasking of investigators
T3	LackOfOutcomeMeasurementData 17071 17233	effect of magnesium treatment on cognitive symptoms—which are common after aneurysmal subarachnoid haemorrhage—might have been missed by the modified Rankin Scale
T4	LackOfOutcomeMeasurementData 17238 17404	measured clinical outcome 3 months after haemorrhage, which is a usual period for outcome assessment in stroke studies, and although a benefit might be detected later
T5	OutcomeMeasures 16087 16269	study was pragmatically designed to assess whether magnesium improved clinical outcome after aneurysmal subarachnoid haemorrhage, we chose poor outcome as our primary outcome measure
T6	OutcomeMeasures 16362 16429	did not include delayed cerebral haemorrhage as a secondary outcome
T7	OutcomeMeasures 16455 16498	did not include other baseline measurements
